NR1I2 and cancer: It has been shown that PXR protects cells against liver injury/DNA damage induced by carcinogens and anti-cancer drugs, such as polycyclic aromatic hydrocarbons (PAHs) and their metabolites, aflatoxin B 93, 94, alkylating agents (cyclophosphamide, nimustine, lomustine) 95, anthracyclines (doxorubicin, daunorubicin and adriamycin) 96 and platinum-based compounds (loplatin, oxaliplatin, cisplatin) 97.